Tag Archives: clinical inertia

Introduction Dapagliflozin is a well-established treatment for type 2 diabetes mellitus (T2DM) that belongs to a class of medications called sodium-glucose cotransporter type 2 inhibitors (SGLT2i). It exerts its hypoglycaemic effect through reversibly inhibiting SGLT2 in the renal proximal convoluted tubule to reduce glucose re-absorption and increase urinary glucose excretion. Several well-designed randomised-controlled trials were conducted to assess the cardiovascular safety and efficacy of dapagliflozin, when administered at a dose of 10 mg once daily, in reducing cardiovascular events and related hospitalisations associated with heart f